IPCALAB - Swing Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Swing Trade Rating: 3.9

📊 Technical Assessment

Current Price ₹1,488 is above both 50 DMA (₹1,432) and 200 DMA (₹1,420) — bullish alignment.

RSI (58.6) — near breakout momentum but not yet overbought.

MACD (25.6) — strongly positive, suggesting active upward trend.

Volume significantly below weekly average — needs confirmation for broader participation.

💰 Fundamental Snapshot

Valuation

P/E (44.6) vs Industry PE (34.0) — priced at a notable premium.

PEG (–30.1) — reflects valuation stress due to weak growth adjustment; cautionary flag.

Profitability

ROCE (14.7%) & ROE (12.8%) — moderately healthy.

EPS ₹29.1 — solid earnings anchor.

Debt-to-Equity (0.20) — fairly low, supportive of financial stability.

Quarterly PAT Decline (₹248 Cr → ₹180 Cr) — recent drop may weigh on sentiment.

🏦 Institutional Sentiment

FII Change: –0.08% — nearly flat, neutral posture.

DII Change: +0.15% — modest accumulation.

📥 Entry Strategy

Preferred Entry Range: ₹1,475–₹1,485

Confirm entry if

RSI pushes above 60

MACD maintains upward slope

Volume jumps above 2L

📤 Exit Strategy (If Holding)

Profit Booking Zone: ₹1,530–₹1,550 — recent resistance levels.

Momentum Target: ₹1,580–₹1,610 — requires RSI > 65 and MACD expansion.

Full Exit Zone: ₹1,675+ — contingent on breakout volume and bullish strength.

🧠 Final Word

IPCALAB shows a technically bullish chart with decent fundamentals, though its PEG and declining PAT suggest caution. It's a viable swing candidate if momentum continues and volume supports the move. Set tight stops and monitor RSI-MACD confluence for trend conviction.

Want me to map out other pharma stocks showing volume spikes and RSI strength? There are a few breakout candidates shaping up.

Edit in a page